Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 2/20 | 0.57 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | SPR | P35270 | 2/20 | 0.46 |
| ▸ | FHIT | P49789 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179158 | 0.85 | CBFB (0.65) | CBFBNPC1RAB9ARUNX1TP53 | |
| SCHEMBL1662758 | 0.80 | CHEK2 (0.76) | CHEK2NPC1RAB9AMAPTKDM4E | |
| SCHEMBL125632 | 0.80 | CBFB (0.82) | CBFBNPC1RAB9ARUNX1MAPT | |
| SCHEMBL18365268 | 0.79 | METAP2 (0.59) | CHEK2NPC1RAB9ATDP1KDM4E | |
| SCHEMBL179109 | 0.79 | METAP2 (0.60) | CBFBCHEK2NPC1RAB9ATP53 | |
| SCHEMBL125168 | 0.79 | CBFB (0.83) | CBFBNPC1RAB9ARUNX1TP53 | |
| SCHEMBL12470518 | 0.79 | POLB (0.54) | CHEK2TP53POLBMAPTTDP1 | |
| SCHEMBL7405989 | 0.79 | F2 (0.54) | NPC1RAB9AKDM4ESPRFHIT | |
| SCHEMBL1664788 | 0.78 | CHEK2 (0.68) | CHEK2NPC1RAB9ATP53POLB | |
| SCHEMBL828113 | 0.77 | KDM4E (0.56) | CHEK2NPC1RAB9ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3670509-B1 | INHIBITORS OF INV(16) LEUKEMIA | UNIV VIRGINIA PATENT FOUNDATION (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-3670509-A1 | INHIBITORS OF INV(16) LEUKEMIA | The University of Virginia Patent Foundation (US) | 2020-06-24 | — | — | EP | disclosed |
| US-9926290-B2 | Inhibitors of INV(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2016-04-07 | — | — | US | disclosed |
| US-9221764-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8748618-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2010132684-A9 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010132684-A2 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CBFB 3/4885CHEK2 1583/4885NPC1 1794/4885 |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CBFB 3/4885CHEK2 1479/4885NPC1 1798/4885 |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CBFB 3/4885CHEK2 1479/4885NPC1 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.